Papsidero L D, Nemoto T, Snyderman M C, Chu T M
Cancer. 1979 Nov;44(5):1636-40. doi: 10.1002/1097-0142(197911)44:5<1636::aid-cncr2820440515>3.0.co;2-c.
Levels of Clq binding activity have been measured in the sera of patients with benign and malignant breast disease. Cancer patients showed significantly higher binding activity than patients with gross fibrocystic disease. Clq binding levels were not related to levels of carcinoembryonic antigen, or rheumatoid factor. The Clq reactive material was identified as being precipitable with Protein A, and predominantly eluted in gel filtration fractions with a molecular weight of approximately 1 x 10(6). These studies indicate that Clq binding level may be of use in the differential diagnosis of benign and malignant breast disease.
已对患有良性和恶性乳腺疾病患者的血清中Clq结合活性水平进行了测量。癌症患者的结合活性显著高于患有严重纤维囊性疾病的患者。Clq结合水平与癌胚抗原或类风湿因子水平无关。Clq反应性物质被鉴定为可被蛋白A沉淀，并且在凝胶过滤级分中主要以分子量约为1×10(6)洗脱。这些研究表明，Clq结合水平可能有助于乳腺良性和恶性疾病的鉴别诊断。
